These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34421820)

  • 1. Isomer-Resolved Imaging of Prostate Cancer Tissues Reveals Specific Lipid Unsaturation Profiles Associated With Lymphocytes and Abnormal Prostate Epithelia.
    Young RSE; Claes BSR; Bowman AP; Williams ED; Shepherd B; Perren A; Poad BLJ; Ellis SR; Heeren RMA; Sadowski MC; Blanksby SJ
    Front Endocrinol (Lausanne); 2021; 12():689600. PubMed ID: 34421820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.
    Randall EC; Zadra G; Chetta P; Lopez BGC; Syamala S; Basu SS; Agar JN; Loda M; Tempany CM; Fennessy FM; Agar NYR
    Mol Cancer Res; 2019 May; 17(5):1155-1165. PubMed ID: 30745465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
    Furusato B; Shaheduzzaman S; Petrovics G; Dobi A; Seifert M; Ravindranath L; Nau ME; Werner T; Vahey M; McLeod DG; Srivastava S; Sesterhenn IA
    Prostate Cancer Prostatic Dis; 2008; 11(2):194-7. PubMed ID: 17768422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
    Angel PM; Spruill L; Jefferson M; Bethard JR; Ball LE; Hughes-Halbert C; Drake RR
    Prostate; 2020 Sep; 80(13):1071-1086. PubMed ID: 32687633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.
    Song H; Weinstein HNW; Allegakoen P; Wadsworth MH; Xie J; Yang H; Castro EA; Lu KL; Stohr BA; Feng FY; Carroll PR; Wang B; Cooperberg MR; Shalek AK; Huang FW
    Nat Commun; 2022 Jan; 13(1):141. PubMed ID: 35013146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
    Butler LM; Mah CY; Machiels J; Vincent AD; Irani S; Mutuku SM; Spotbeen X; Bagadi M; Waltregny D; Moldovan M; Dehairs J; Vanderhoydonc F; Bloch K; Das R; Stahl J; Kench JG; Gevaert T; Derua R; Waelkens E; Nassar ZD; Selth LA; Trim PJ; Snel MF; Lynn DJ; Tilley WD; Horvath LG; Centenera MM; Swinnen JV
    Cancer Res; 2021 Oct; 81(19):4981-4993. PubMed ID: 34362796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
    Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
    Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocryphal FADS2 activity promotes fatty acid diversification in cancer.
    Young RSE; Bowman AP; Williams ED; Tousignant KD; Bidgood CL; Narreddula VR; Gupta R; Marshall DL; Poad BLJ; Nelson CC; Ellis SR; Heeren RMA; Sadowski MC; Blanksby SJ
    Cell Rep; 2021 Feb; 34(6):108738. PubMed ID: 33567271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.
    Goto T; Terada N; Inoue T; Kobayashi T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Utsunomiya N; Makino Y; Sumiyoshi S; Yamasaki T; Kamba T; Ogawa O
    Prostate; 2015 Dec; 75(16):1821-30. PubMed ID: 26332786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atlas of Ex Vivo Prostate Tissue and Cancer Images Using Confocal Laser Endomicroscopy: A Project for Intraoperative Positive Surgical Margin Detection During Radical Prostatectomy.
    Panarello D; Compérat E; Seyde O; Colau A; Terrone C; Guillonneau B
    Eur Urol Focus; 2020 Sep; 6(5):941-958. PubMed ID: 30683530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study.
    Cahill LC; Fujimoto JG; Giacomelli MG; Yoshitake T; Wu Y; Lin DI; Ye H; Carrasco-Zevallos OM; Wagner AA; Rosen S
    Mod Pathol; 2019 Jul; 32(8):1158-1167. PubMed ID: 30914763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
    Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
    Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid.
    Hayes GM; Simko J; Holochwost D; Kuchinsky K; Busch R; Misell L; Murphy EJ; Carroll P; Chan J; Shinohara K; Hellerstein MK
    Clin Cancer Res; 2012 Jun; 18(12):3250-60. PubMed ID: 22553345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells.
    Anttinen M; Yli-Pietilä E; Suomi V; Mäkelä P; Sainio T; Saunavaara J; Eklund L; Blanco Sequeiros R; Taimen P; Boström PJ
    Int J Hyperthermia; 2019; 36(1):915-925. PubMed ID: 31466481
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolomic signatures of aggressive prostate cancer.
    McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
    Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP3
    Davidsson S; Andren O; Ohlson AL; Carlsson J; Andersson SO; Giunchi F; Rider JR; Fiorentino M
    Prostate; 2018 Jan; 78(1):40-47. PubMed ID: 29105795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues.
    Jaraj SJ; Egevad L
    APMIS; 2010 May; 118(5):383-8. PubMed ID: 20477814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.
    Banerjee S; Zare RN; Tibshirani RJ; Kunder CA; Nolley R; Fan R; Brooks JD; Sonn GA
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3334-3339. PubMed ID: 28292895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Murphy GP; Busch C; Abrahamsson PA; Epstein JI; McNeal JE; Miller GJ; Mostofi FK; Nagle RB; Nordling S; Parkinson C
    Scand J Urol Nephrol Suppl; 1994; 162():7-42; discussion 115-27. PubMed ID: 7817162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.